ArticleActa dermato-venereologica2026
Clinical and Pathological Predictors of Unfavourable Outcomes in Thin and In Situ Melanomas: A Retrospective Cohort Study from Taiwan.
Article in Acta dermato-venereologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thin melanoma, defined as tumour thickness ≤1.0 mm, and melanoma in situ are increasingly diagnosed. However, acral-predominant Asian populations appear to experience higher rates of adverse outcomes than Western cohorts. This study aimed to identify prognostic factors among Taiwanese patients with early-stage melanoma. We reviewed 178 melanoma in situ/thin melanoma cases diagnosed from 1995 to 2025 at a tertiary centre and analysed overall survival, melanoma specific survival, recurrence-free survival, and distant metastasis-free survival using Cox and Fine-Gray competing-risk models. During a mean follow-up of 81 months, adverse events were not uncommon, including recurrence (8.8%), distant metastasis (4.7%) and melanoma-specific mortality (5.1%). Age was the most consistent predictor across endpoints in both Cox and competing-risk analyses. A Breslow thickness ≥0.8 mm independently increased the risk of melanoma-specific mortality, whereas ulceration and mitotic activity were not significant predictors. In conclusion, melanoma in situ and thin melanoma in this acral-predominant Asian cohort are not uniformly low risk. Older patients or those with tumours approaching or exceeding 0.8 mm in thickness warrant closer, risk-adapted surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.